#United States #New York #Class Action #Securities Fraud #Skye Bioscience

Levi & Korsinsky Advises on Class Action Lawsuit Against Skye Bioscience

Levi & Korsinsky, LLP has formally alerted investors of Skye Bioscience, Inc. regarding a class action lawsuit that seeks to compensate those affected by potential securities fraud. The complaints focus on the company's lead product, nimacimab, which is alleged to have been misrepresented to investors, leading them to inaccurately assess its effectiveness and regulatory approvals.

Understanding the Class Action

The class action lawsuit pertains to losses sustained by Skye Bioscience investors within the specified window from November 4, 2024, to October 3, 2025. This span is critical for those looking to file claims and seek restitution for their investments. The legal action is spearheaded by allegations suggesting that the company inflated the prospects of nimacimab, thus misleading investors about its viability.

Key Allegations

The claims detail significant discrepancies, including:

• - Ineffectiveness of nimacimab: The lead product candidate, nimacimab, was reportedly not as effective as the company portrayed.
• - Overstated prospects: Statements regarding the clinical and regulatory landscape surrounding nimacimab were allegedly exaggerated, which left investors unaware of the true status of the product.
• - Materially false claims: Throughout the pertinent time frame, the statements made by the company's officials are described as misleading, impacting investment decisions.

What Investors Should Know

Investors impacted by these events must act swiftly. The deadline for filing a request to be appointed as the lead plaintiff is set for January 16, 2026. Being appointed leads to the possibility of a more significant role in proceedings, but it isn’t a requirement for claiming compensation. Notably, any class member can pursue their claim without having to incur out-of-pocket costs, making participation financially accessible.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has been a leading name in securities litigation for more than two decades, successfully securing hundreds of millions for investors. Their experienced team is dedicated to representing shareholders caught in complex legal situations, and they have a stellar reputation, reflected in their ranking among the top securities litigation firms in the U.S.

Next Steps for Affected Investors

If you believe you're affected by this situation regarding Skye Bioscience, immediate action is crucial. Investors can collect more information and formally join the class action through a dedicated link provided by Levi & Korsinsky. Moreover, their professionals, including Joseph E. Levi, are available to assist via direct communication channels, ensuring that every affected investor can understand their rights and options moving forward.

In conclusion, this class action lawsuit serves as an essential reminder of the importance of transparency from corporations to their investors. Those believing they have suffered due to misleading information from Skye Bioscience are encouraged to explore their legal options as the deadline approaches.